Natco Pharma gets approval for its partner’s ANDA for Cabazitaxel Intravenous Solution

25 Jul 2022 Evaluate

The U.S. Food and Drug Administration (USFDA) has granted approval to Natco Pharma’s partner Breckenridge Pharmaceutical Inc’s Abbreviated New Drug Application (ANDA) for Cabazitaxel Intravenous Powder (generic for Jevtana Kit) for the 60mg/1.5mL (40mg/mL) strength.

Breckenridge and Natco are unable to make further comment regarding the launch date for the product, as that is confidential and cannot be disclosed at this time. According to industry sales data, Jevtana Kit generated annual sales of $303 million during the twelve months ending May 2022.

Natco Pharma was promoted as a private company to be in the business of research, developing, manufacturing and marketing of pharmaceutical substances and finished dosage forms for Indian and International markets.

Natco Pharma Share Price

891.40 -4.50 (-0.50%)
30-Dec-2025 10:09 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1716.00
Dr. Reddys Lab 1269.65
Cipla 1487.75
Zydus Lifesciences 899.70
Lupin 2081.50
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×